CTHIn ForceLegislation
Therapeutic Goods Regulations 1990
Sch 4Therapeutic goods required to be included in the part of the Register for listed goods
Start here
Get a plain-English read of Sch 4
Turn the raw legal text into a practical explanation grounded in Therapeutic Goods Regulations 1990.
Schedule 4—Therapeutic goods required to be included in the part of the Register for listed goods
(regulation 10)
| Item No. | Therapeutic goods |
| -------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 1 | therapeutic goods manufactured in Australia for export only other than goods exempt under regulation 12 |
| 3 | medicines where:(a) the medicine only contains ingredients that are specified in a determination under paragraph 26BB(1)(a) of the Act; and(b) if a determination under paragraph 26BB(1)(b) of the Act specifies requirements in relation to ingredients being contained in the medicine—none of the requirements have been contravened; and(c) the ingredients in the medicine are not of a kind required to be sterile; and(ca) the medicine does not contain a substance included in a Schedule to the Poisons Standard; and(d) the medicine only has indications that are covered by a determination under paragraph 26BF(1)(a) of the Act; and(e) if a determination under paragraph 26BF(1)(b) of the Act specifies requirements in relation to the indications—none of the requirements have been contravened |
| 4A | homoeopathic preparations where:(a) the preparation consists of, or contains a dilution of, mother tincture that is a 1,000 fold dilution, or a lesser dilution, of that mother tincture; and(b) the preparation only contains ingredients that are specified in a determination under paragraph 26BB(1)(a) of the Act; and(c) if a determination under paragraph 26BB(1)(b) of the Act specifies requirements in relation to ingredients being contained in the preparation—none of the requirements have been contravened; and(d) the preparation is not required to be sterile; and(e) the preparation does not contain a substance (other than one that is more than a 1,000‑fold dilution of mother tincture) included in a Schedule to the Poisons Standard; and(f) the preparation only has indications that are covered by a determination under paragraph 26BF(1)(a) of the Act; and(g) if a determination under paragraph 26BF(1)(b) of the Act specifies requirements in relation to the indications—none of the requirements have been contravened |
| 5 | homoeopathic preparations where:(a) each dilution is more dilute than a 1,000 fold dilution of mother tincture; and(b) the preparation only contains ingredients that are specified in a determination under paragraph 26BB(1)(a) of the Act; and(c) if a determination under paragraph 26BB(1)(b) of the Act specifies requirements in relation to ingredients being contained in the preparation—none of the requirements have been contravened; and(d) the preparation is not required to be sterile; and(e) the preparation only has indications that are covered by a determination under paragraph 26BF(1)((a) of the Act; and(f) if a determination under paragraph 26BF(1)(b) of the Act specifies requirements in relation to the indications—none of the requirements have been contravened |
| 7 | sunscreen preparations for dermal application, if:(a) the claimed sun protection factor has been established by testing according to the method described in Australian/New Zealand Standard AS/NZS 2604:2021, Sunscreen products ‑ Evaluation and classification, published jointly by, or on behalf of, Standards Australia and Standards New Zealand, as in force from time to time; and(b) the performance statements and markings on the label comply with that Standard; and(c) the sunscreen preparation only contains ingredients that are specified in a determination under paragraph 26BB(1)(a) of the Act; and(d) if a determination under paragraph 26BB(1)(b) of the Act specifies requirements in relation to ingredients being contained in the sunscreen preparation—none of the requirements have been contravened; and(e) the sunscreen preparation only has indications that are covered by a determination under paragraph 26BF(1)(a) of the Act; and(f) if a determination under paragraph 26BF(1)(b) of the Act specifies requirements in relation to the indications—none of the requirements have been contravened |
| 8 | medicines to be listed under section 26AE of the Act, if:(a) the medicine only contains ingredients that are specified in a determination under paragraph 26BB(1)(a) of the Act; and(b) if a determination under paragraph 26BB(1)(b) of the Act specifies requirements in relation to ingredients being contained in the medicine—none of the requirements have been contravened; and(c) the ingredients in the medicine are not of a kind required to be sterile; and(ca) the medicine does not contain a substance included in a Schedule to the Poisons Standard; and(d) the indications proposed by the sponsor of the medicine are either:(i) uses of the medicine in preventing, curing or alleviating a disease, ailment, defect or injury in persons, other than a form of the disease, ailment, defect or injury that, under the Therapeutic Goods Advertising Code, is a serious form; or(ii) uses of the medicine in connection with alleviating a disease, ailment, defect or injury in persons, being a form of the disease, ailment, defect or injury that, under the Therapeutic Goods Advertising Code, is a serious form; and(e) the indications proposed by the sponsor of the medicine do not refer to an indication that is or contains a prohibited representation (within the meaning of Part 5‑1 of the Act |
| 12 | kits (to be known as medicine kits) consisting as follows:(a) solely of medicines—if Part 3‑2 of the Act applies to any of the individual therapeutic goods contained in the kit;(b) of medicines and biologicals—if:(i) Part 3‑2 of the Act applies to any of the individual therapeutic goods (other than biologicals) contained in the kit; and(ii) Part 3‑2A of the Act applies to any of the biologicals contained in the kit |
| 16 | hospital grade disinfectants, or household grade disinfectants, that are claimed to be sterilants, fungicides, sporicides, tuberculocides or virucides |
| 17 | a therapeutic vaping kit, if each of the goods in the kit is a registered good |